CS
DOVA

Candriam SCA’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Candriam SCA’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-233,200
Closed -$2.07M – 854
2019
Q1 		$2.07M Hold
233,200
– – 0.03% 490
2018
Q4 		$1.77M Hold
233,200
– – 0.03% 485
2018
Q3 		$4.89M Buy
233,200
+114,000
+96% +$2.71M 0.07% 321
2018
Q2 		$3.57M Buy
119,200
+39,200
+49% +$1.07M 0.06% 362
2018
Q1 		$2.17M Buy
+80,000
New +$2.39M 0.04% 465

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Candriam SCA's DOVA Position: Q2 2019 in Review

Candriam SCA sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q2 2019, closing a stake of 233,200 shares — an estimated $2.07M sold.

Candriam SCA first reported a position in DOVA in Q1 2018 and held it in 5 quarters. The position peaked at $4.89M in Q3 2018. 66 funds tracked by Wall St. Rank hold DOVA as of Q2 2019.

  • Candriam SCA reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Candriam SCA sold 233,200 Dova Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $2.07M.
  • Candriam SCA first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
  • Candriam SCA's Dova Pharmaceuticals, Inc. Common Stock position peaked at $4.89M in Q3 2018.
  • 66 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.